missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Rebastinib, MedChemExpress
MedChemExpress Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.
Brand: Medchem Express HY-13024
This item is not returnable.
View return policy
Description
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.Specifications
| Rebastinib | |
| Off-White | |
| C30H28FN7O3 | |
| DCC-2036 | |
| CC(C)(C)C1=NN(C(NC(NC2=C(F)C=C(OC3=CC(C(NC)=O)=NC=C3)C=C2)=O)=C1)C4=CC=C5C(C=CC=N5)=C4 | |
| 553.59 | |
| Research | |
| Cancer-Kinase/protease |
| 1020172-07-9 | |
| Research | |
| 50 mg | |
| DMSO : 50 mg/mL (90.32 mM; ultrasonic and warming and heat to 80°C) | |
| 553.59 | |
| 98.0% | |
| Powder |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Rebastinib, MedChemExpress
Research purposes only
Spot an opportunity for improvement?Share a Content Correction
